Liquidia settles all pending litigation with United Therapeutics, agrees to USD 380.7 million net payment

By Public Technologies
  • Liquidia entered a global settlement with United Therapeutics that ends all pending litigation between the companies.
  • Deal follows a Sept. 30, 2026 Delaware court ruling that two claims of United Therapeutics’ ’327 patent were valid and infringed.
  • Liquidia agreed not to appeal. It filed a label supplement removing the PH-ILD indication for YUTREPIA.
  • Financial terms include a net USD 175 million payment within 30 business days. Additional USD 145.4 million is due in early 2027.
  • Liquidia will pay USD 60.3 million to resolve third-party interests tied to treprostinil injection antitrust litigation. Promotional support ends.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-115672), on October 14, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.